Revolutionizing developments in biological
tissue vales will drive the European transcatheter heart valve implantation
market to over $1.7 Billion by 2020
According
to a new report on the European Market for Cardiac Surgery Devices, the leading
global authority in medical device and pharmaceutical market research, the
total European Cardiac Surgery Devices market is projected to grow to over $3.4
Billion by 2020. The strongest market fueling this growth is the transcatheter
heart valve devices, which is comprised of both the transcatheter heart valve
implantation (THVI) and the transcatheter mitral valve repair (TMVR) segments.
Currently, the only THVI product available on the market is transcatheter
aortic valve implantation (TAVI) devices. However transcatheter mitral valve
implantation (TMVI) devices are being developed and are expected to receive CE
approval by 2020.
With
an aging population and increasing prevalence of obesity, the number of
patients suffering from heart failure in Europe will continue to grow. Mitral
regurgitation (MR) is the second most common heart valve disease in Europe and
affects millions of patients worldwide. “TMVR is a less invasive treatment
option for MR than open surgery making it more appealing for patients. These
factors will continue to drive the market which is projected to grow to over
12% by 2020. There are currently only two players in this market, Abbott with
their MitraClip™, the world’s first TMVR device, and Cardiac Dimensions.
The
transcathether heart valve implantation device market is expected to grow over
10% by 2020. This market is comprised of the transcatheter aortic valve
implantation (TAVI) and the transcathether mitral valve implantation (TMVI). As
of 2013 only TAVI products have been approved in Europe. Leading the TAVI
market is Edwards Lifesciences, who recently introduced their new product
SAPIEN 3®, Boston Scientific, recently received CE market certification for its
Lotus™ Valve System as well as, Medtronic, JenaValve, St Jude Medical, Sorin
and Direct Flow Medical.
Recent
developments for the treatment of aortic heart valve conditions have been
generating much interest amongst the international cardiac community.
Biological tissue valves is a newer and a less invasive treatment option for
aortic heart valve conditions as opposed to the traditional open surgery.
Tissue
valves have been gaining popularity over the alternative mechanical valves. They
are biocompatible and do not require a lifelong treatment of medication. TAVI
procedures are an appealing treatment option for patients with late stage heart
failure and or are too ill to undergo a more invasive treatment.
The
global series “Markets for Cardiac Surgery Devices” covering the U.S., Asia and
15 countries in Europe. The full reports provide a comprehensive analysis
including procedure numbers, units sold, market value, forecasts, as well as a
detailed competitive market share and analysis of major plays’ success
strategies in each market and segment.
The
report also covers markets for: tissue heart valve, mechanical heart valve,
annuloplasty repair, transcatheter mitral valve repair (TMVR), transcatheter
heart valve implantation (THVI), on-pump CABG, off-pump CABG, endoscopic vessel
harvesting (EVH), anastomosis assist, cardiac ablation, transmyocardial
revascularization (TMR), ventricular assist device (VAD), intra-aortic balloon
pump (IABP), artificial heart, patent foramen ovale (PFO), atrial sept defect
(ASD) and ventricular septal defect (VSD) device markets.
Spanning over 464 pages, “European
Market for Cardiac Surgery Devices 2014” report covering the Executive
Summary, European Cardiac Surgery Device Market, Procedures, Country Profiles,
Tissue Heart Valve Market, Mechanical Heart Valve Market, Annuloplasty Repair
Device Market, Transcatheter Mitral Valve Repair Market, Transcatheter Heart
Valve Implantation Market, On-Pump Coronary Artery Bypass Device Market,
Off-Pump Coronary Artery Bypass Device Market, Endoscopic Vessel Harvesting
Device Market, Anastomosis Assist Device Market, Cardiac Ablation Device
Market, Transmyocardial Revascularization Market, Ventricular Assist Device
Market, Intra-Aortic Balloon Pump Device Market, Artifical Heart Device Market,
Patent Foramen Ovale Device Market,
Atrial And Ventricular Septal Device Market. The report covered 14 companies
- Medtronic, Edwards LifeSciences, St. Jude Medical, Maquet, Sorin, Thoratec,
Abbott Vascular, Biosense Webster, W. L. Gore, Boston Scientific, Terumo,
JenaValve, AtriCure, Direct Flow Medical
See Table of contents &
Purchase this publication at: - http://mrr.cm/ZWv
No comments:
Post a Comment
Note: only a member of this blog may post a comment.